Trial Profile
A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
- Indications Angelman syndrome
- Focus Adverse reactions
- Acronyms STARS
- Sponsors Ovid Therapeutics
- 12 Dec 2020 Results published in the Neurology
- 08 Dec 2020 Results evaluating novel EEG markers in patients with Angelman Syndrome, presented at the 74th Annual Meeting of the American Epilepsy Society
- 23 Nov 2020 According to an Ovid Therapeutics media release, data from this trial will be presented at the American Epilepsy Society (AES) 2020 Virtual Congress 2020.